Clinical and Cost Effectiveness of Bevacizumab + FOLFIRI Combination Versus FOLFIRI Alone as First-Line Treatment of Metastatic Colorectal Cancer in South Korea

Clinical Therapeutics

Volumn 34, Issue 6, 2012, Pages 1408-1419

  Lee, Eui Kyung ^a   Revil, Cedric ^b   Ngoh, Charles A ^b   Lister, Johanna ^c   Kwon, Jeong Mi ^d   Park, Mee Hye ^a   Park, Seok Jin ^d   Park, Young Suk ^e   Shin, Sang Joon ^f   Lee, Myung Ah ^g   Lee, Nam Su ^h   Zang, Dae Young ⁱ   Bae, Eun Jin ^j   Kang, Mi Jeong ^j  

^a Sungkyunkwan University   (South Korea)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c Analytica International Inc   (Germany)

^d Sookmyung Women's University   (South Korea)

^e Sungkyunkwan University School of Medicine   (South Korea)

^f Yonsei University College of Medicine   (South Korea)

^g The Catholic University of Korea College of Medicine   (South Korea)

^h Soonchunhyang University College of Medicine   (South Korea)

ⁱ Hallym University College of Medicine   (South Korea)

^j Roche Korea Co Ltd   (South Korea)

more..

Author keywords

Antineoplastic combined chemotherapy protocol; Bevacizumab; Colorectal neoplasms; Cost effectiveness; Indirect comparison; Republic of Korea

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SENSITIVITY ANALYSIS; SOUTH KOREA;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; FLUOROURACIL; HUMANS; LEUCOVORIN; NEOPLASM METASTASIS; REPUBLIC OF KOREA;

EID: 84862145212     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.05.001     Document Type: Article

References (53)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Bae J.M., Jung K.W., Won Y.J. Estimation of cancer deaths in Korea for the upcoming years. J Korean Med Sci 2002, 17:611-615.
3. Ferlay J., Shin H.R., Bray F., et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide Accessed January 21, 2011. http://globocan.iarc.fr.
4. Jansman F.G., Postma M.J., Brouwers J.R. Cost considerations in the treatment of colorectal cancer. Pharmacoeconomics 2007, 25:537-562.
5. Redaelli A., Cranor C.W., Okano G.J., Reese P.R. Screening, prevention and socioeconomic costs associated with the treatment of colorectal cancer. Pharmacoeconomics 2003, 21:1213-1238.
6. Rougier P., Mitry E. Epidemiology, treatment and chemoprevention in colorectal cancer. Ann Oncol 2003, 14(Suppl 2):ii3-ii5.
7. Kelly H., Goldberg R.M. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005, 23:4553-4560.
8. Meyerhardt J.A., Mayer R.J. Systemic therapy for colorectal cancer. N Engl J Med 2005, 352:476-487.
9. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041-1047.
10. Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22:23-30.
11. Kohne C.H., Van C.E., Wils J., et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005, 23:4856-4865.
12. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000 September 28, 343(13):905-914.
13. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22:229-237.
14. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001, 280:C1358-C1366.
15. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
16. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7:987-989.
17. Fuchs C.S., Marshall J., Mitchell E., et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007, 25:4779-4786.
18. Fuchs C.S., Marshall J., Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 2008, 26:689-690.
19. Guan Z.Z., Yu J.M., Luo R.C., et al. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J Cancer 2011, 30:682-689.
20. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
21. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21:60-65.
22. Kabbinavar F.F., Hambleton J., Mass R.D., et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005, 23:3706-3712.
23. Saltz L.B., Clarke S., Diaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019.
24. Stathopoulos G.P., Batziou C., Trafalis D., et al. Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncology 2010, 78:376-381.
25. Kabbinavar F., Kozloff M. Regarding 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'. Oncology 2011, 80:135-137.
26. Cacheux W., Le T.C., Baranger B., et al. Targeted biotherapy in metastatic colorectal carcinoma: current practice. J Visc Surg 2011, 148:12-18.
27. Koukourakis G.V., Sotiropoulou-Lontou A. Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer. Clin Transl Oncol 2011, 13:710-714.
28. Reuters Currency Rates Accessed February 25, 2011. http://uk.reuters.com/business/currencies/quote?srcAmt=1.00%26srcCurr=KRW%26destAmt=%26destCurr=USD%26historicalDate=
29. Pharmacoeconomic Evaluation Guidelines Korea 2011, Korea Health Insurance Review Agency.
30. National Cancer Registry Annual Report 2009, Korea Ministry of Health & Welfare.
31. 5th Korean Human Dimensions Research Report 2004, Korean Agency for Technology and Standards.
32. Arnold D, Kindler M, Petersen V, et al. Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: first results from a large community-based observational cohort study in Germany. Presented at: 2010 Gastrointestinal Cancers Symposium; Orlando, Fla; January 22-24, 2010. Abstract 439.
33. Grothey A., Sugrue M.M., Purdie D.M., et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008, 26:5326-5334.
34. Van C.E., Rivera F., Berry S., et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009, 20:1842-1847.
35. Weighted Average Price Per Components of Drugs 2011, Korea Health Insurance Review Agency.
36. Medical Insurance Fee Files 2011, Korea Health Insurance Review Agency.
37. Pemetrexed for the First-Line Treatment of Non-Small-Cell Lung Cancer [TA181] 2009, National Institute for Health and Clinical Excellence (NICE), Report no. TA181.
38. Cost Statistics 2010, Korea Health Insurance Review Agency.
39. Cassidy J., Clarke S., Diaz-Rubio E., et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008, 26:2006-2012.
40. Cotrim H., Pereira G. Impact of colorectal cancer on patient and family: implications for care. Eur J Oncol Nurs 2008, 12:217-226.
41. Summary of opinion (post authorisation) Avastin (bevacizumab) European Medicines Agency, Accessed June 27, 2011. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000582/smops/Positive/human_smop_000208.jsp%26murl=menus/medicines/medicines.jsp%26mid=WC0b01ac058001d127%26jsenabled=true.
42. Final Labeling Text Avastin US Food and Drug Administration, Accessed June 27, 2011. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory.
43. NCCN Clinical Practice Guidelines in Oncology. Rectal Cancer V.2 National Comprehensive Cancer Network, Accessed November 1, 2011. http://www.nccn.org/professionals/physician_gls/PDF/rectal.pdf.
44. NCCN Clinical Practice Guidelines in Oncology. Colon Cancer V.2 National Comprehensive Cancer Network, Accessed November 1, 2011. http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf.
45. Hedden L., Kennecke H., Villa D., et al. Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada. Eur J Cancer February 9, 2012, [Epub ahead of print].
46. Yang H., Yu A.P., Wu E.Q., et al. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer. J Med Econ 2011, 14:542-552.
47. Asseburg C., Frank M., Kohne C.H., et al. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. Clin Ther 2011, 33:482-497.
48. Pharmaceutical Economic Evaluation Guidelines-Republic of Korea 2006.
49. Synovate Oncomonitor (metastatic colorectal cancer) 2010.
50. Guidelines for Preparing Submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3) 2008, Australian Government Department of Health and Ageing, Therapeutic Goods Administration.
51. Glenny A.M., Altman D.G., Song F., et al. Indirect comparisons of competing interventions. Health Technol Assess 2005, 9. 1-iv.
52. Dranitsaris G., Edwards S., Edwards J., et al. Bevacizumab in combination with FOLFIRI chemotherapy in patients with metastatic colorectal cancer: an assessment of safety and efficacy in the province of Newfoundland and Labrador. Curr Oncol 2010, 17:12-16.
53. Sobrero A., Ackland S., Clarke S., et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 2009, 77:113-119.